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first medlcal intervention to hospital admission (60 vs 103 min, p<O.O2) were markedly 
shorter in EMS group. We also observed a significant increase in reperfusion therapy at 
the acute phase tn EMS group compared to OMC group (respectively 70 % vs 48 %, 
p<O.O03), mainly due to a higher rate of primary angioplasty (respectively 33 % vs 20 %, 
~~0.04). Conclusion. Our study in real world collecting data from a French regional pop- 
ulation demonstrated that only a small rate of patients use the direct call tc EMS at symp- 
toms onset of MI. This study also documents the beneficial effect of a direct call to EMS 
by reducing the pre-hospital delays and by Increasing the rate of early revascularisation. 
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tion) and in 2001 (after last pathway’s’ revision) were rewewed. A STEMI was diagnosed 
at ED in 52015,066 (10.3%) chest pain pts in 1997, and in 452/4,843 (9.3%) chest pain 
pts in 2001. Pts were managed according to the ED cardiologist’s decisions I” 1997, 
whereas entered the pathway for STEMI in 2001, with pre-defined criteria for diagnosis, 
thrombolysis, percutaneous coronary intervention (PCI) and admission to CCU. 
Results: Comparison of treatment modalities disclosed that mwe pts were given throm- 
bolysis in 1997 (49% vs 16%. p<O.O5). whereas in 2001 more pts were sent to PCI (63% 
vs 1 l%, ~~0.05). In 2001, also. pts received more often aspirin (90% vs 61%. ~~0.05) 
and i.v. beta-blocker (60% vs 35%. ~~0.05) soon after arrival at ED. Comparison 
between 1997 and 2001 revealed similar admission rates to CCU (69% vs 78%, NS) or 
cardiac wards (19% vs IO%, NS). Conversely, with respect to 1997, pts hospitakzed in 
2001 had shorier length-of-stay (12+5 vs 18s days, pcO.05) as well as lower major 
adverse coronary events (21% vs 30%, ~~0.05) and lower all-cause In-hospital moriality 
(12% vs 20%, p<O.O5). The quality of care indicators improved with time. as door-to-ECG 
interval (lM_6 vs 1969 min. p<O.O5), door-to-needle time (Z&l0 vs 35110 min. ~~0.05). 
and door-to-balloon Interval (70215 vs 99&?0 min, ~~0.05) were shorter in 2001 than I” 
1997. 
Background. Glycoproteln Ilb-llla Inhibitors (GPls) have been shown to improve the out- 
comes of patients with acute coronary syndromes. Recent reports have suggested that 
many Ml patients who may be eligible for GPls still do not receive these treatments. 
Methods. We examined the prevalence of GPI use in the NRMI 4 (Jul 2000 - Apr 2001) 
and created a predictive model to bener ascertain the factors associated with GPI use. In 
order to minimize selection bias and confounding. we selected patients who received 
cardiac catheterization and presented at fully interventional capable hospitals. Patients 
who had contralndications to GPI and who were transferred-out to another hospital were 
excluded from this study. Results. 
Conclusions: A critical pathway for STEMI at ED increases the use of evidence-based 
treatment strategies and improves outcome and quality of care of pts presenting to an 
ED because of acute chest pain. 
1147-97 Use of Reperfusion Therapy in Patients Presenting With 
ST Elevation Myocardial Infarction: Findings From The 
TETAMI Study and TETAMI Registry (The Safety and 
Efficacy of Subcutaneous Enoxaparin Versus 
Intravenous Unfractionated Heparin and of Tirofiban 
Versus Placebo in the Treatment of Acute Myocardial 
Infarction) 
Utilization of GP Ilb-llla Inhibitors (GPls) after MI, N = 24,438 
GPI No GPI 
CATH: N = 24,438 
Elective PCI. N = 6,086 
Primary PCI: N = 1,314 
43.4% 56.6% 
77.4% 22.6% 
86.8% 13.2% 
MY analysis of the factors associated with GPI use 
Non-Whites 
Women 
Age 10 years 
History CHF 
Prior MI 
Medicare (YS FFS) 
COPD 
Smoker 
West (vs Midwest) 
South (vs Midwest) 
Anterior Ml 
Prior CABG 
Prior PTCA 
LBBB 
Chest pain 
Odds Ratlo P value 
0.80 < 0.001 
0.90 0.001 
0.92 < 0.001 
0.83 0.002 
0.87 < 0.001 
0.88 0.002 
0.90 0.03 
1.11 0.003 
1.17 < 0.001 
1.17 < 0.001 
1.21 < 0.001 
1.16 < 0.001 
1.31 < 0.001 
1.59 < 0.001 
1.72 < 0.001 
OR < 1 .O associated with less use; OR > 1 .O more use 
Conclusion. Less than half of oatients with Ml who mav be elioible for GPls act&Iv 
received these therapies. M&ties. women and increasing age were important factors 
associated with less use, though chest pain on initial presentation and prior coronary 
revascularization were associated with more use. 
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Improved Treatment Modalities and Outcome for 
Patients With ST Elevation Myocardial Infarction 
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Background: The use of protocols for pts with ST elevation myocardial infarction 
(STEMI) is growing, but no definite conclusion regarding the value of critlcal pathways 
has been drawn. Aim of this study was to investigate the impact of a critical pathway on 
processes of care and outcome for pts accessing the emergency department (ED) 
because of a possiale STEMI. 
Methods: Critical pathways for management of acute chest paIn and STEMI at our ED 
were developed in 1998 and revised every year. Accordingly, the records of all pts who 
were referred because of chest pain to the ED in 1997 (before pathways’ implementa- 
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Early treatment with lytics or primary PCI reduces the mortality rate of STEMI patients. 
Pts presenting >12 h are generally considered to be ineligible for repelfusion therapy, 
and there are currently no specific treatment recommendations. 
Methods: Patients with STEMI ~24 h who are ineligible for acute reperfusion, have no 
cardiogenic shock and with no revascularization scheduled within 48 h were included in 
the TETAMI study and randomized to 1 of 4 antithrombotic regimens involving enox- 
aparin or UFH in combination with tirofiban or placebo for 2-8 days. A concurrent registry 
tracked STEMI patients reperfused ~12 h and non-repedused patients presenting <24 h 
and not enrolled in TETAMI. We compared the demographics and clinical outcomes of 
1397 pts ineligible for acute reperiusion with 1146 pts eligible for reperfusion. 
Results: Outcomes are presented below. The major reason for not using reperfusion 
therapy was late presentation. Repeiiused registry patients were younger: aged 61, com- 
pared with 63 and 67 years for TETAMI patients and non-reperfused registry patients; 
more likely to be male (78%. 73% and 63%, respectively), and had persistent ST eleva- 
tion as opposed to LBBB or Q waves. Reperfused registry patients had better outcomes 
even after adjusting for admisslon Killip class. TETAMI patients had better outcomes 
than non-reperfused registry patients. 
Conclusion: These data highlight the need for new therapeutic strategies for this high 
risk patient cohort. 
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Background Up to l/3 of stable post-MI patlents have an occluded infarct-related artery 
(IRA). OAT is an international, randomized trial designed to determlne If benefit exists in 
opening the occluded IRA 3-28 days post-MI in asymptomatic. high-risk patients. As of 91 
l/02, 911 patients were randomized. The purpose of this interim analysis is to define 
characteristics that correlate with practice differences in the care of acute Ml I” OAT sites 
in the US, Canada and other countries. A criterion for SelectIon of an OAT site was the 
availability of an experienced PCI operator who met rigorous standards. 
Methodology In order to define the population of MI patients from which OAT patients 
